Fig. 3From: Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trialsThe pooled risk ratio (RR) of 75% responder rate (defined as patients with a 75% reduction in migraine days from baseline) in different treatment doses compared with placebo, the diamond indicates the estimated RR with 95% confidence interval (CI) for the pooled patientsBack to article page